| Expression pattern: |
DN |
| Associated gene: |
Smad7, Ago2 |
| Associated microRNA: |
miR-17-5p |
| Biological function: |
inhibits hepatic stellate cells activation and suppresses liver fibrosis progression; inhibits cell proliferation and cell cycle progression in TGF-beta1-treated HSCs |
| Molecular mechanism: |
circMTO1 acts as a miRNA sponge for miR-17-5p, thereby regulating Smad7 and suppressing TGF-beta1-induced HSC activation |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (inhibits); cell cycle (inhibits); fibrosis (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Western Blot; Clinical Sample Validation; ROC Analysis; Survival Analysis |
| Clinical significance: |
Serum circMTO1 was negatively correlated with fibrosis stages as well as HAI scores and may serve as a diagnostic biomarker for liver fibrosis in CHB patients; in HCC, high circMTO1 expression was associated with higher survival rate. |
| Description: |
circMTO1 is down-regulated in serum of CHB patients with liver fibrosis and decreases further with increasing fibrosis/HAI scores, supporting diagnostic potential. Functionally, circMTO1 suppresses TGF-beta1-induced hepatic stellate cell activation by sponging miR-17-5p, thereby relieving repression of Smad7. |
| Confidence score: |
0.7972 |